Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Duke's McClellan: Changing Drug Development Policy From Outside FDA

Sep 28 2016

• By Sue Sutter

Related Content

Expedited Approval Pathway Concept Draws Strong Support But Different Proposals

Dec 05 2011

Totality Of ‘Breakthrough’ Evidence Guides FDA Designation Decisions

May 04 2015

FDA Launches Compendium Of Clinical Outcome Assessments With Eye On Patients

Jan 13 2016

Real-World Evidence: Efficacy Assessments Await FDA Clarity, Pilot Projects

Mar 14 2016

Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

Sep 21 2016

Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program

Jul 16 2016

FDA To Join The 'Real World' Under PDUFA VI

Jul 16 2016

Additional Topics

Policy Drug Approval Standards Drug Safety BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window